Clinical Trial Update: Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone [Phase 2]

View source ↗

Summary

Phase IIb study evaluating BAY94-8862 for safety and efficacy in worsening chronic heart failure with left ventricular systolic dysfunction, with or without chr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure
• Left Ventricular Systolic Dysfunction
• Type 2 Diabetes Mellitus

Drugs mentioned

• BAY94-8862

Snippet

Sponsor: Bayer | Conditions: Heart Failure | Phase 2 | Status: COMPLETED